Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.

Umberto PensatoCarlo BaraldiValentina FavoniMaria Michela CainazzoPaola TorelliPietro QuerzaniAlessia PascazioDavide MascarellaEleonora MatteoSimone QuintanaGian Maria AsioliPietro CortelliGiulia PierangeliSimona GuerzoniSabina Cevoli

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)

Erenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients.

Keyphrases

end stage renal disease
ejection fraction
healthcare
chronic kidney disease
newly diagnosed
chronic pain
peritoneal dialysis
prognostic factors
adverse drug
emergency department
neuropathic pain